title: [Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)].
abstract: OBJECTIVE
  Phase II clinical trails showed that paclitaxel is effective in treatment of advanced gastric cancer (AGC). The combination of paclitaxel and 5-fluorouracil (5-FU) in the treatment of advanced gastric cancer is effective and safe. This study was designed to evaluate the efficacy and the toxicity of paclitaxel combined with semimonthly 5-FU/Leucovorin for the AGC patients.
  
  
  METHODS
  Twenty-five measurable patients with AGC proved pathologically were enrolled into this study. The chemotherapy regimen was comprised of paclitaxel,75 mg/m(2) i.v. in a 3-hour infusion followed by 2-hour infusion of leucovorin 200 mg/m(2), then 10-minute intravenous bolus of 5-FU 375 mg/m(2), then 48-hour infusion of 5-FU 2.8 g/m(2) using an ambulatory pump. The regimen was given per 14 days. One cycle consisted of twice chemotherapy regimens. All enrolled patients received at least two cycles of treatment.
  
  
  RESULTS
  After two cycles of chemotherapy, the complete remission and the partial remission were 8% and 60%, respectively. The median duration of response was 4 months. No treatment-related death occurred. Phlebitis,feeling disorder, and alopecia were main side effects.
  
  
  CONCLUSIONS
  Semimonthly 5-FU/LV combined with paclitaxel has high release rate but comparatively mild toxicity for AGC patients.
authors.affiliation: Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.
authors.forename: Ning-Ning
authors.initials: NN
authors.lastname: Zhou
authors.forename: Zhong-Mei
authors.initials: ZM
authors.lastname: Zhou
authors.forename: Mao-Zhen
authors.initials: MZ
authors.lastname: Liu
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Li
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Xu
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Teng
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Xiang
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Tian
authors.forename: Dong-Geng
authors.initials: DG
authors.lastname: Liu
authors.forename: Pi-Li
authors.initials: PL
authors.lastname: Hu
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.forename: Hui-Juan
authors.initials: HJ
authors.lastname: Qiu
authors.forename: Sui-Yi
authors.initials: SY
authors.lastname: Qian
authors.forename: You-Jian
authors.initials: YJ
authors.lastname: He
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D017239:Paclitaxel; D002955:Leucovorin; D005472:Fluorouracil